Garcinia Cambogia, Diabetic Ketoacidosis, and Pancreatitis by Bystrak, Tamara et al.
University of Rhode Island
DigitalCommons@URI
Pharmacy Practice Faculty Publications Pharmacy Practice
2017
Garcinia Cambogia, Diabetic Ketoacidosis, and
Pancreatitis
Tamara Bystrak
Miguel E. Cervera-Hernandez
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs
The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy
Articles, as set forth in our Terms of Use.
This Article is brought to you for free and open access by the Pharmacy Practice at DigitalCommons@URI. It has been accepted for inclusion in
Pharmacy Practice Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Bystrak, T., Cervera-Hernandez, M. E., Reddy, N., King, Z., & Bratberg, J. (2017). Garcinia Cambogia, Diabetic Ketoacidosis, and
Pancreatitis. Rhode Island Medical Journal, 100(10), 48-50.
Available at: http://rimed.org/rimedicaljournal/2017/10/2017-10-48-case-bystrak.pdf
Authors
Tamara Bystrak, Miguel E. Cervera-Hernandez, Nishitha Reddy, Zachary King, and Jeffrey P. Bratberg
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/php_facpubs/96
 Garcinia Cambogia, Diabetic Ketoacidosis, and Pancreatitis 
Tamara Bystrak, PharmD, Miguel E. Cervera-Hernandez, MD, Nishitha Reddy, MD, Zachary 
King, PharmD, Jeffrey Bratberg, PharmD 
 
 
Key Words 
garcinia cambogia, hydroxycitric acid, pancreatitis, diabetic ketoacidosis 
 
Introduction 
Obesity affects 36.5% of all American adults,1 and many people struggle to achieve sustained 
weight-loss. Lifestyle modifications like dieting and exercising are effective, but difficult, so 
patients often try dietary supplements to more quickly and easily lose weight.  However, 
supplement intake is not without its risks. Dietary supplement products are portrayed as 
treatment of a disease, despite insufficient evidence to support their use. Furthermore, a recent 
report analyzing emergency room visits due to supplement intake showed that 25.5% of cases 
implicated a weight-loss product.2 
 
Garcinia cambogia (GC) is a dietary supplement marketed primarily for weight loss, as well as 
for appetite suppression, cholesterol reduction, and blood sugar control. Hydroxycitric acid 
(HCA) is the active ingredient in GC products. The primary mechanism of action of HCA for 
weight loss is via inhibition of adenosine triphosphatase (ATP) citrate-lyase, preventing the 
conversion of citrate to oxaloacetate and acetyl coenzyme A (ACA). Inhibiting the formation of 
oxaloacetate and ACA reduces fatty acid synthesis in the cell cytosol.3 There have been several 
reports of adverse effects associated with consumption of GC including hepatotoxicity,4 
rhabdomyolysis,5 nephropathy,6 serotonin toxicity7 and cardiovascular toxicity.8 We report the 
case of a 56-year-old woman who presented with diabetic ketoacidosis (DKA), pancreatitis, and 
stress cardiomyopathy after several weeks of GC consumption. 
 
Case Report 
A 56-year-old woman with a history significant for insulin-dependent diabetes mellitus, 
hypertension, hepatitis C infection, and opioid abuse, abstinent for more than 18 years, presented 
to the emergency room with altered mental status. On the day of admission, she had been found 
by her son in the bathroom, lethargic and confused. Earlier that day, she had reported mild 
abdominal pain and vomiting. Her outpatient medications had not been significantly adjusted in 
the last three years (Table 1). On admission, her pulse was 103 beats/min and regular, respiratory 
rate 24 breaths/ min, blood pressure 115/70 mmHg, and temperature 95.8 degrees Fahrenheit. Her 
Glasgow Coma Scale was 13. There were no focal neurological deficits, and her mucous mem-
branes were dry. Initial laboratory data was significant for a plasma glucose of 1,150 mg/dL, 
arterial pH of 7.33, serum bicarbonate of 7 mmol/L, serum beta hydroxybutyrate of 5.4 mmol/L, 
serum anion gap of 35, troponin I of 5.12 ng/mL, and serum lipase of 861 U/L. A computed 
tomography of the abdomen without contrast showed peripancreatic stranding, as well as possible 
pancreatic atrophy. Initial electrocardiogram revealed normal sinus tachycardia without acute ST-
segment changes.  
 
The patient was admitted to the intensive care unit for management of DKA, pancreatitis and 
elevated troponin. She was treated with aggressive hydration, insulin drip, and electrolyte 
repletion. Her DKA and pancreatitis resolved within three days. Her mental status improved in 
three days and she reported excellent adherence to all of her medications and no dietary 
transgressions. In fact, she had been trying and had successfully lost approximately 40 pounds in 
the last month. When the medical team inquired further, the patient admitted to taking GC for the 
last month. She had been taking two tablets of GC by mouth three times a day with meals 
(1,400–1,440mg HCA per day depending on the brand) in addition to taking an unknown 
quantity of another dietary supplement, Irvingia gabonensis or African Mango. Her hospital 
course was complicated by atrial fibrillation with rapid ventricular response, which was treated 
with amiodarone. A transthoracic echocardiogram revealed significantly depressed left 
ventricular function. The mid to distal anterolateral, anteroseptal, inferior, and entire apical wall 
appeared severely hypokinetic, consistent with stress cardiomyopathy. The patient was 
discharged after seven days, fully recovered. 
 
Discussion 
Pancreatitis is caused by inflammation, leading to inappropriate activation of amylase and lipase 
and autodigestion of the gland. Pancreatitis can be idiopathic or caused by gallstones, alcohol, 
illicit drugs, infections, diabetic ketoacidosis, or medications. Typical cases of medication-
induced pancreatitis involve antimicrobials, valproic acid, furosemide, thiazide diuretics, 
immunosuppressants, NSAIDs, tamoxifen, L-asparaginase, and estrogen.9 Of these agents, the 
patient had only reported taking her prescription aspirin and hydrochlorothiazide. Case reports 
have suggested that a few other medications on her list may rarely cause pancreatitis: statins, 
angiotensin converting enzyme (ACE) inhibitors, and metformin.10  
 
Diabetic ketoacidosis is a physiological adaptation to starvation. Common causes of DKA are 
insulin non-adherence, starvation, infection, acute stress, pancreatitis, or medications including 
antipsychotics, cocaine, alcohol, corticosteroids, glucagon, interferon, sympathomimetics, and 
thiazide diuretics. DKA is more common in Type I diabetes than Type II diabetes. When cells 
lack sufficient intracellular glucose to function, the body begins breaking down fat. ACA is then 
metabolized to acetone, acetoacetate, and beta hydroxybutyrate (ketone bodies) rather than 
entering the citric acid cycle. The accumulation of ketone bodies lowers pH and patients often 
experience nausea, vomiting, abdominal pain, confusion, hyperglycemia, and ketonuria. By los-
ing 40 pounds in one month, the patient was essentially in starvation mode.11,12  
 
Based on the mechanism of action, it is possible that GC caused her weight loss, in addition to 
the unwanted side effects of DKA and pancreatitis. GC works to reduce weight by altering the 
availability of oxaloacetate and ACA, but this may also alter glucose and fatty acid metabolism. 
Low levels of oxaloacetate shunt ACA from the citric acid cycle to the ketogenic pathway.13 This 
patient was already at risk for ketosis due to her sudden weight loss. Therefore, GC could have 
caused ketosis both indirectly through weight loss, and directly by inhibiting the production of 
oxaloacetate and shunting ACA into the ketogenic pathway.  
 
Since being featured on television and endorsed by celebrities, GC has been widely used by 
women for weight loss, despite lack of evidence to support efficacy or safety. Various products 
recommend different daily doses of GC and contain different percentages of HCA. There is no 
standardized dosing for GC, and clinical trial doses vary from 1g to 2.8g of HCA daily. A meta-
analysis of twelve small, randomized, double-blinded placebo controlled trials demonstrated a 
statistically significant difference in weight loss versus placebo, with an average of -1% body 
weight loss in the HCA group versus placebo. Of note, all twelve studies had at least one 
methodological weakness and provided little or no information regarding blinding procedure, 
allocation, or randomization. A sub-analysis of the two highest quality GC trials from the meta-
analysis showed no statistical difference between groups.14  
 
Since the passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994, 
dietary supplements have been recognized as a distinct class of products that contain a vitamin, 
mineral, herb/botanical, or amino acid, intended for ingestion for the purpose of supplementing 
the diet. While medications in the US must be approved by the FDA before marketing, dietary 
supplements are not held to these standards of safety and efficacy. The FDA only regulates 
dietary supplements to ensure that good manufacturing practices and minimum labeling 
requirements are met. Therefore, the primary method of identifying potential dietary supplement 
toxicity is through post-market patient reports. Manufacturers are required to report serious 
adverse events to the FDA. Health care professionals, public health officials, researchers, and 
citizens are also encouraged to report dietary supplement adverse events to the FDA.15  
Hepatic toxicity associated with the use of GC has been reported for over a decade,4 but 
pancreatitis may be an under-recognized adverse effect. There is only one other published case 
of pancreatitis associated with GC. In 2016, a middle-aged woman with a history of type 2 
diabetes mellitus, hypertension, and chronic hepatitis C developed acute pancreatitis after using 
GC for weight loss.16 While a home medication list was not included in this case report, it seems 
reasonable to assume that the patient case from 2016 and our patient would be taking similar 
drugs due to overlapping comorbidities of diabetes, hypertension, and opioid use disorder. As 
previously stated, thiazide diuretics, ACE inhibitors, statins, aspirin, and metformin have all been 
associated with acute pancreatitis.10 However, our patient had been receiving these medications 
chronically, with no recent dose changes and no previous episodes of pancreatitis. The 
supplements may have had an additive effect in these two patients with high baseline risk.  
While no definitive cause was determined, the use of GC may have contributed to her DKA and 
pancreatitis based on the Naranjo algorithm for estimating adverse drug reaction causality.17 
Each of the ten questions in the algorithm is scored, and the total is summed. The likelihood of 
an adverse drug-event is categorized as definite, probable, possible, or doubtful based on high to 
low total score. The patient’s total score was five, which coincides with a probable adverse 
drug reaction. 
 
Conclusion 
Garcinia cambogia supplements may have serious adverse effects, especially in patients with 
pre-existing metabolic disorders. Patients may not always mention their dietary supplement use 
during medication reconciliation and may be surprised to learn that dietary supplements can 
potentially be deleterious to their health. Our patient assumed that GC must be safe because it 
was endorsed by a trusted TV figure. 
Providers must be sure to identify patients that use dietary supplements, counsel these patients on 
their risks, and report any possible adverse effects to the FDA. 
(FDA Safety Reporting Portal at US Department of Health and Human Services: 
https://www.safetyreporting.hhs.gov) 
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Image 1: Garcinia cambogia, a topical fruit found in the forests of Southeast Asia, India, 
and Africa.   
Attribution: Vssun at ml.wikipedia 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Outpatient Medications on Admission. 
Drug, Dose, Route, Frequency Indication 
 Diazepam, 10 mg, PO, daily  Anxiety 
 Methadone, 125 mg, PO, daily  Opioid abuse 
 Aspirin, 81mg, PO, daily  Primary prevention 
 Metoprolol tartrate, 25 mg, PO, twice daily  Hypertension 
 Metformin, 1,000 mg, PO, twice daily  Diabetes mellitus 
 Hydrochlorothiazide, 12.5 mg, PO, daily  Hypertension 
 Lisinopril, 5 mg, PO, daily  Hypertension 
 Atorvastatin, 20 mg, PO, daily  Hyperlipidemia 
 Insulin glargine, 75 U, SubQ, daily  Diabetes mellitus 
NOTE: PO - by mouth; SubQ - subcutaneous.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
